Dr. Mohamad M. Al-Rahawan
Claim this profileUMC Cancer Center / UMC Health System
Studies Cancer
Studies Neuroblastoma
23 reported clinical trials
74 drugs studied
Area of expertise
1Cancer
Stage I
Stage II
Stage IV
2Neuroblastoma
MYC positive
Stage IV
MYC negative
Affiliated Hospitals
Clinical Trials Mohamad M. Al-Rahawan is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Mohamad M. Al-Rahawan
Clinical Trial Related7 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Mohamad M. Al-Rahawan has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Doxorubicin Hydrochloride
- Radiation Therapy
- Dexamethasone
Breakdown of trials Mohamad M. Al-Rahawan has run
Cancer
Neuroblastoma
Lymphoma
Germ Cell Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mohamad M. Al-Rahawan specialize in?
Mohamad M. Al-Rahawan focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage II.
Is Mohamad M. Al-Rahawan currently recruiting for clinical trials?
Yes, Mohamad M. Al-Rahawan is currently recruiting for 5 clinical trials in Lubbock Texas. If you're interested in participating, you should apply.
Are there any treatments that Mohamad M. Al-Rahawan has studied deeply?
Yes, Mohamad M. Al-Rahawan has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Mohamad M. Al-Rahawan?
Apply for one of the trials that Mohamad M. Al-Rahawan is conducting.
What is the office address of Mohamad M. Al-Rahawan?
The office of Mohamad M. Al-Rahawan is located at: UMC Cancer Center / UMC Health System, Lubbock, Texas 79415 United States. This is the address for their practice at the UMC Cancer Center / UMC Health System.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.